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Abstract
Background: Continuous use of anabolic androgenic steroid in high-doses is associated with substantial health
risks, including hepatocellular adenoma. Malignant transformation from hepatocellular adenoma to hepatocellular
carcinoma after anabolic androgenic steroid abuse has been rarely reported. The morphological distinction of
adenoma from well-differentiated hepatocellular carcinoma is challenging and requires elaborated imaging
techniques and histology.
Case presentation: We report about a 29-year old male professional bodybuilder who presented with
mid-epigastric pain at the emergency unit. Ultrasound showed a severe hepatomegaly with multiple lesions.
Contrast-enhanced ultrasound revealed a heterogeneous pattern with signs of hepatocellular carcinoma. CT
scan of the abdomen confirmed multiple hypervascular lesions and central areas of necrosis without contrast
enhancement. Subsequent diagnostics included fine needle aspiration (FNA) of suspicious lesions and mini-laparoscopy
to establish the diagnosis of a β-catenin and testosterone-receptor positive hepatocellular carcinoma embedded in
multiple adenomas. The patient was subsequently treated by liver transplantation and remains tumor-free 27 month
after surgery.
Conclusion: Hepatocellular carcinoma occurring in association with anabolic androgenic steroid abuse should sensitize
physicians and especially professional bodybuilders for the harmful use of high doses of steroids.
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Background
One of the major risk factors of developing hepatocel-
lular adenoma (HCA) is the use of oral contraceptives,
which stimulate liver expressed estrogen and androgen
receptors, predominantly in women between 15 and
45 years of age [1, 2]. Accordingly, 90 % of HCA are di-
agnosed in women [3]. Other risk factors include glyco-
gen storage disease I and III and treatment with anabolic
steroids in patients with Fanconi’s anemia [4–6]. A few
reports indicate that anabolic androgenic steroids (AAS)
may also lead to the formation of HCA [7–9]. Relevant
complications of HCA include hemorrhage and malignant
transformation into hepatocellular carcinoma (HCC) de-
pending on size and β-catenin activation.
In the literature are more reports of patients with
Fanconi’s anemia, which received medical treatment with
AAS and subsequently developed HCCs [4, 6]. Further-
more a few cases are described from bodybuilders with
AAS abuse that subsequently developed HCC [7, 9, 10].
These patients require close surveillance to detect pos-
sible malignant transformation from HCA into HCC or
lesions that are at risk of bleeding or rupture [8].
Here, we report a case of a testosterone-receptor posi-
tive HCC arising from multiple HCAs in a professional
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bodybuilder after 6 years of AAS abuse and the difficul-
ties of diagnostics and therapeutical options.
Case presentation
Clinical history
We describe a case of a 29-year old male professional
bodybuilder who presented at the emergency unit with
midepigastric-pain. He had been taking anabolic andro-
genic steroids (AAS; see below) and underwent strict
nutritional diets to increase muscle mass prior to com-
petitions over the last 6 years. He self-administered the
following AAS from 2011 to 2012 in cycles of 4 weeks
with rest periods of several weeks between the cycles: nan-
drolone decanoate (400 mg/week), sustanon (750 mg/
week), methandienone (280–350 mg/week), stanozolol
(50 mg/day for 1 month) and human growth hormone
(4 IE/day for 3 month). Additionally 3 days before compe-
titions he self-administered the diuretics aldosterone
(50 mg/day) and thiazide (25 mg/day) to reduce extracel-
lular and subcutaneous tissue volume and to achieve a
better muscle shaping. Furthermore insulin injections
and tamoxifen were administered. The frequency of self-
administration was varying in each cycle.
At presentation, the patient had not taken any AAS
for 5 weeks. Previous history was a childhood near a nu-
clear power plant until the age of fifteen. Allergic coryza
and nasal spray use since the age of seven were reported.
Moreover no abuse of ethanol or smoking was given.
The patient’s father died supposedly as the result of
kidney cancer, his grandfather died from bronchial
cancer. His mother and younger siblings are healthy. On
examination, the patient showed a three-fold amplified
liver extending into lesser pelvis with painful palpation.
No other clinical abnormalities were detectable (Fig. 1).
Laboratory findings
Laboratory evaluation revealed severe hepatic inflamma-
tion and an impaired liver function (ALT 1653 IU/l; AST
1437 IU/l; alkaline phosphatase 372 IU/l; GGT 463 IU/l;
CHE 1.29 kU/I; LDH 695 U/I; total bilirubin 41 μmol/l;
direct bilirubin 38 μmol/l). Hematology showed an anemia
and slightly increased white blood cell count (leucocytes
12.500/ μl; hemoglobin 8.5 g/dl; INR 1.04; reticulocytes
104/nl). Inflammation parameters were increased (CRP
81 mg/l, PCT 4.8 μg/l, Ferritin 1672 μg/l). The renal
function was almost normal (creatinine 123 μmol/l, but
cystatine c 0.76 mg/l and MDRD> 60 ml/min).
Coagulation tests were normal, as well as hepatitis
virus markers, including hepatitis A, B and C and also
human deficiency virus markers were negative. Serum
levels of sex hypophyseal hormones (LH <0.07 U/I, FSH
<0.3 U/I, androgens (T + DHT) 0.037 ng/ml, free-
testosterone 4.94 pg/ml) and thyroid gland markers
(fT3, fT4) were below the lower limit of normal. This
constellation of sex hormones reflects anabolic steroids
induced hypogonadism (ASIH).
Imaging
Abdominal ultrasound (US) showed a marked hepatomeg-
aly with 25.6 cm in the midclavicular line and 30.1 cm in
the median with evidence of fatty liver. In B-mode sonog-
raphy multiple lesions were detected in both liver lobes
(left liver lobe: various isoecogenic, inhomogeneous lesions
with a maximum size of 92 mm × 92 mm; right liver lobe:
various isoecogenic, polycyclic inhomogeneous lesions with
a maximum size of 222 mm × 162 mm) (Fig. 2a). More-
over, the hepatic segment of the inferior vena cava (IVC)
was compressed by the hepatic tumors, which consecu-
tively led to a partial Budd Chiari syndrome. This was
Fig. 1 Clinical examination showed a muscular body, height 186 cm, weight 120 kg. The lung showed a sonorous percussion, vesicular breath
sounds, no noise. Heart: regular rhythm, 55 bpm, RR 134/67 mmHg, first heart sound and second heart sound not flashy, no heart murmurs. No
pathological examination findings for head, neck, lymph node status, pulse status. No scleral icterus. Abdominal examination showed a large
abdomen, vascular abdominal markings, yellow colouring, liver palpable to lesser pelvis right, superficial palpation was painful, spleen not
palpable, no kidney pain or back pain (a lateral view; b ventral view)
Solbach et al. BMC Gastroenterology  (2015) 15:60 Page 2 of 7
diagnosed in the doppler sonography through the retro-
grade flow pattern in the right hepatic vein with an evi-
dence of subcapsular venous collaterals.
In contrast-enhanced ultrasound (CEUS) the hepatic
lesions showed a heterogeneous pattern (Fig. 2b). Some
lesions exhibited arterial enhancement, initially at the
periphery with subsequent very rapid centripetal filling
and without wash-out in the portal venous or late phase.
Other lesions showed arterial enhancement, with a cha-
otic vascular pattern and avascular areas in different
parts of each tumor. In the portal venous phase, these
tumors showed wash-out, especially in liver segment 6,
in which a tumor biopsy was performed. The small
lesions (diameter <12 mm) seen in B-mode sonography
showed neither arterial hypervascularisation nor wash-
out in the portal venous or late phase. The contrast-
enhanced CT scan of the abdomen revealed a distinctive
hepatomegaly with multiple hypervascular lesions with-
out substantial wash-out in portal venous phase. In the
largest lesions, central areas of necrosis without contrast
enhancement were present (16 × 13 cm) (Fig. 3). There
was no evidence of metastasis in the abdomen and chest.
Pathology
Cytology of liver-segment six was performed by fine nee-
dle aspiration (FNA) of one lesion with signs of hepatocel-
lular carcinoma in contrast-enhanced ultrasound. The
cytological samples did not reveal malignancy and showed
no clearly signs for hepatocellular carcinoma or hepato-
blastoma. Further molecular cytogenetic and pathological-
anatomical diagnostics showed atypical HCA.
To confirm the diagnosis of hepatocellular carcinoma
in suspicious lesions, a diagnostic laparoscopy was per-
formed. The liver was enormously enlarged and there
was almost no veritable parenchyma visible between the
tumor nodules. The largest tumors bulged out of the
liver’s surface with yellow to bluish discoloration and
strong tumor vascular markings. Biopsy of the liver in
the right lobe from three tumors and one tumor of the
left lobe was performed. The synopsis of morphology
Fig. 2 a B-mode ultrasonography: The hepatic tumors were polycyclic, isoechoic and inhomogeneous. Doppler sonography showed a compression in
the IVC hepatic segment by the liver tumors with consecutive development of partial Budd Chiari syndrome diagnosed by the retrograde flow pattern
in the right hepatic vein and the presence of subcapsular venous collaterals. b Contrast enhanced ultrasonography (CEUS): CEUS was performed using
a bolus injection of 1.5 mL SonoVue® (Bracco SpA, Milan, Italy). The largest lesion showed a large, avascular center with hypervascular margin in the
arterial phase. In the late venous phase parts of the center and the margin showed wash-out
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and immunohistochemistry now clearly confirmed the
diagnosis of a hepatocellular carcinoma (Fig. 4d; β-catenin
20% nuclear positive (Fig. 4a), glutamine synthetase
cytoplasmic positive (Fig. 4b), androgen-receptor nuclear
positive (Fig. 4c) and focal CD34 positive). Sequence
analysis of exon 3 of the β-catenin gene was performed by
PCR and subsequent Sanger sequencing as described in
reference eleven and showed a hotspot mutation in codon
32 (p.D32G) [11].
Treatment
Due to the size and number of the lesions, there was no
option for surgical resection. The distinction of all tumor
nodules into HCAs and hepatocellular carcinomas was
impossible, but overall HCC burden was considered to be
out of the Milan criteria [12]. The multidisciplinary tumor
board at Medical School Hannover initially recommended
chemoembolization, which was however declined by the
patient. He therefore returned home, where subsequently
a liver transplantation was performed without any compli-
cations. The explanted liver showed a mass of 8 kg.
27 months after transplantation he is in excellent condi-
tion without any signs of metastasis or local recurrence.
He is not taking AAS anymore.
Discussion
We report a case of a young professional bodybuilder
with self-administration of high-doses of anabolic andro-
genic steroids (AAS) for at least 6 years who developed
a hepatocellular carcinoma (HCC) without metastasis or
alpha-fetoprotein elevation. In this case, the hepato-
cellular carcinoma was embedded in multiple hepato-
cellular adenomas (HCA).
Fig. 3 Contrast enhanced computed tomography in arterial (a,c) and portalvenous phase (b,d): Highly enlarged liver with curved borders secondary to
multiple parenchymatous lesions throughout all liver segments, with arterial enhancement and no substantial wash-out during portalvenous phase.
The large lesion in right lobe up to 16 cm appeared inhomogeneous with peripheral enhancement and non-enhancing, necrotic areas in the center.
Intrahepatic vena cava and right liver vein were completely compressed by nodular tumors in the caudate lobe and the large lesion in the right lobe
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AAS such as testosterone and its derivates are favored
in endurance and strength sports as well as in body-
building, often in combination with other medication
like diuretics and insulin. The most popular oral prod-
ucts especially stanozolol, methandrostenolone and nan-
drolone have a high first-pass in the liver and have been
reported to induce significant toxicity including intrahe-
patic structural changes with cholestasis and benign and
malignant tumors.
It has been reported, that steroids induce HCA with
potential malignant transformation into carcinoma. As
described for colorectal-carcinoma, there could be an
adenoma-carcinoma sequence [13]. In our case, it is
difficult to distinguish whether the HCC developed de
novo or within the multiple HCAs. Several biopsies from
multiple tumor nodules were required to ascertain the
diagnosis of HCC. The morphological distinction of HCA,
focal nodular hyperplasia (FNH), macroregenerative nod-
ules from well-differentiated HCC can be challenging [14].
Malignant transformation of HCA may occur in about
4.5–9 % of cases [14–17]. Exome sequencing has identified
recurrent somatic activating mutations in several genes in-
cluding FRK, JAK1, gp130, and β-catenin. Moreover, inte-
grative analysis of HCAs transformed to hepatocellular
carcinoma revealed that β-catenin mutation occurs as an
early alteration, whereas TERT promoter mutations are
associated with the last step of the adenoma-carcinoma
transition [18]. HCAs with ß-catenin mutations frequently
show an overexpression of β-catenin (nuclear and cyto-
plasmic) and glutamine synthetase as in our patient.
Although HCA shows an increased prevalence in women,
beta-catenin activation is more prevalent in men with con-
sequently an increased prevalence of HCC [19, 20]. In our
case genetic analysis for β-catenin mutations showed a
hotspot mutation in codon 32 of exon 3 (p.D32G).
As has been described previously, HCA showed highly
variable appearance on computed tomography (CT), mag-
netic resonance imaging (MRI), and contrast-enhanced
ultrasound (CEUS) scans. This is reflected by the differ-
ences in the histological features [21–25]. In the CEUS,
typical HCA shows an arterial hypervascularisation in the
early arterial phase with a centripetal filling pattern. How-
ever this arterial enhancement pattern can also be en-
countered in HCC and is not pathognomonic of HCA
[26]. MRI seems to be superior to other imaging modal-
ities for the diagnosis of HCA. One study performed by
Laumonier and coworkers revealed that in hepatocyte nu-
clear factor 1 alpha (HNF1A) -mutated and inflammatory
Fig. 4 Liver biopsy: Small solid and glandular associations of hepatocytes without bile duct epithelia. Reticulin fiber network focally obtained.
The hepatocytes had markedly enlarged nuclei with large nucleoli with coarse structure of chromatin. Iron and rhodanine negative.
Immunohistochemistry: Beta-catenin 20 % nuclear positive (a; 80:1) and glutamine synthetase cytoplasmic positive (b; 160:1), hepatocytes
with nuclear positivity for androgen-receptors (c; 140:1). Molecular Cytogenetics: Aneuploidy of chromosome 1 (CEP1) and 8 (CEP). Diagnosis:
The results of conventional histology, molecular biology and immunohistochemistry recommended HCC G1 (d; HE stain 140:1). Comment:
Simply by Cytology (FNP) a detection of HCC G1 is quite difficult. There were no bridges or cell atypia, on the other hand, histology showed
more criteria for HCC G1
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HCAs characteristic MRI patterns exist, which reach a
specificity of 100 % and a sensitivity of 86.7 % [27].
Histology is the ultimate gold standard for the diagnosis
and risk stratification of HCAs [28].
Immunochemistry analysis revealed the presence of
testosterone-receptors on the hepatocellular carcinoma,
which might be of prognostic significance. In one study,
none of the patients with androgen receptor (AR) posi-
tive HCC survived 5 years [29]. Other studies supported
these findings by suggesting a negative impact of AR
positivity on tumor recurrence [30]. Various clinical
trials have evaluated the role of anti-androgens for the
treatment of liver cancer with controversial outcome. In
a systematic review, Di Maio et al. concluded that hor-
monal treatment should not be a part of the current
management of HCC patients [31, 32].
There are different therapeutic strategies for HCC
without metastasis. First of all local ablative therapies
like percutaneous ethanol injection (PEI), radiofrequency
ablation (RFA), transarterial chemoembolization (TACE)
and radiation therapy (RT) but effectiveness depends on
the number and size of the tumors. Due to the tumor
burden of our patient local ablative therapies such as
RFA or surgery were not possible. TACE for bridging
was recommended by the tumorboard, although a clear
differentiation between HCA and carcinoma was not
given. This minimally- invasive method can treat mul-
tiple tumors, can be easily repeated and is well estab-
lished in the treatment algorithm for patients with
advanced HCC [33]. Embolization of HCA has been
rarely reported, but appears to be a feasible therapeutic
option [34]. Our patient refused to take this option.
In general liver transplantation is the therapy of choice
for selected patients with HCC without the possibility of
resection and extrahepatic metastasis [35]. It is known,
that patients exceeding Milan criteria for liver trans-
plantation had a higher recurrence rate and lower survival
rate than complying them. But also beyond the Milan
criteria but within extended University of California, San
Francisco (UCSF) criteria (single tumor <6.5 cm, max-
imum of three total tumors with none >4.5 cm, and
cumulative tumor size <8 cm) a prolonged survival can be
achieved. Survival rates beyond UCSF criteria were less
than 50 % at 5 years [36]. Following liver transplantation,
our patient is still without any signs of tumor recurrence
or metastasis.
Conclusion
In this case, 6 years of chronic anabolic androgenic
steroid abuse lead to HCA and HCC development with
almost no normal liver tissue left. Not only bodybuilders
but also trainers and physicians should be aware of the
HCC risk when using or prescribing AAS.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
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